Latest Recruitment News

RBR Group has secured its first post-restart Mozambique LNG contract, but the A$2 million-scale award arrives alongside just A$32,000 in cash and overdue convertible notes. The company is relying on further contract wins, debt restructuring and new capital to bridge the gap.

OpenLearning reached record SaaS ARR of A$3.44 million after securing more than A$2.8 million in minimum contract value during the quarter. But with only A$204,000 in cash and reported funding of 0.31 quarters, the ASX-listed education software company is preparing an entitlement issue and exploring a placement.

Vertex Minerals has secured approval for round-the-clock underground operations at its Reward Gold Mine, removing the company’s stated biggest production constraint. The operational opening arrives alongside modest quarterly output, a sharply revised resource and reported cash coverage of less than half a quarter.

Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.

Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Catalyst Metals has cut FY27 production guidance to 90,000-105,000 ounces after deferring Trident and Old Highway output to FY28. The downgrade comes despite a stronger balance sheet, a 2Moz Plutonic Reserve base and A$40 million of quarterly cash generation.

Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.

Vitasora Health has signed a Florida healthcare agreement covering an initially addressable 9,000 Medicare patients while estimated October billable care minutes rose 50%. The ASX-listed company also agreed terms for an A$3 million secured facility, but the funding is not yet drawn and carries approval, interest and dilution conditions.

Hiremii’s revenue fell 11.1% to A$7.056 million in Q1 FY2027 as adjusted EBITDA slipped further into loss, testing the company’s transition towards AI-powered workforce intelligence. The new AQYR brand and two platform launches offer a growth narrative, but cash discipline remains central with A$1.789 million of total available funding.

Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.

TALi Digital closed its September quarter with $3.9 million in cash after completing a $3.3 million capital raise and winning shareholder approval for the Datasphere transaction. The company has also exercised an option to negotiate exclusive worldwide rights to Technion in-memory computing technology, although the licence remains unsigned and the technology unproven at commercial scale.